EA201170732A1 - Применение алканоил l-карнитина в комбинации с химиотерапевтическими средствами для лечения новообразований - Google Patents

Применение алканоил l-карнитина в комбинации с химиотерапевтическими средствами для лечения новообразований

Info

Publication number
EA201170732A1
EA201170732A1 EA201170732A EA201170732A EA201170732A1 EA 201170732 A1 EA201170732 A1 EA 201170732A1 EA 201170732 A EA201170732 A EA 201170732A EA 201170732 A EA201170732 A EA 201170732A EA 201170732 A1 EA201170732 A1 EA 201170732A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
carnitine
treatment
combination
kinase inhibitors
Prior art date
Application number
EA201170732A
Other languages
English (en)
Inventor
Клаудио Кавацца
Паоло Карминати
Клаудио Пизано
Original Assignee
Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. filed Critical Сигма-Тау Индустрие Фармасьютике Риуните С.П.А.
Publication of EA201170732A1 publication Critical patent/EA201170732A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к применению алканоил L-карнитина, выбираемому из группы, состоящей из ацетил, пропионил, валерил, изовалерил и бутиррил L-карнитина; в комбинации с одним или более химиотерапевтическими средствами, выбираемыми из группы, состоящей из производных камптотецина; алкилирующих средств; антинеопластических антиметаболитов; соединений платины; ингибиторов топоизомеразы; ингибиторов VEGF; ингибиторов тирозинкиназы; ингибиторов EGFR киназы; ингибиторов mTOR киназы; ингибиторов инсулиноподобного фактора роста 1; ингибиторов Raf киназы, моноклональных антител; ингибиторов протеасом; ингибиторов HDAC; токсинов и имидов для лечения новообразований.
EA201170732A 2008-12-01 2009-12-01 Применение алканоил l-карнитина в комбинации с химиотерапевтическими средствами для лечения новообразований EA201170732A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08170331 2008-12-01
US24854309P 2009-10-05 2009-10-05
PCT/EP2009/066113 WO2010063696A1 (en) 2008-12-01 2009-12-01 Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms

Publications (1)

Publication Number Publication Date
EA201170732A1 true EA201170732A1 (ru) 2011-12-30

Family

ID=40445249

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170732A EA201170732A1 (ru) 2008-12-01 2009-12-01 Применение алканоил l-карнитина в комбинации с химиотерапевтическими средствами для лечения новообразований

Country Status (11)

Country Link
US (2) US20120208883A1 (ru)
EP (2) EP2361086A1 (ru)
JP (2) JP2012510498A (ru)
KR (1) KR20110089402A (ru)
CN (1) CN102215838B (ru)
AU (1) AU2009324183A1 (ru)
CA (1) CA2740347A1 (ru)
EA (1) EA201170732A1 (ru)
HK (1) HK1161114A1 (ru)
MX (1) MX2011005593A (ru)
WO (2) WO2010063696A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011184344A (ja) * 2010-03-08 2011-09-22 Kao Corp ｐ２１発現促進剤
CN101967125B (zh) * 2010-10-08 2012-07-04 广州暨南生物医药研究开发基地有限公司 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用
ES2392879B1 (es) * 2011-05-31 2013-11-04 Servicio Andaluz De Salud Composiciones y preparaciones combinadas de sunitinib y l-carnitina
JP6187470B2 (ja) * 2012-10-15 2017-08-30 旭硝子株式会社 複層ガラスおよび複層ガラスの製造方法
CN105753921B (zh) * 2016-03-31 2019-08-30 沈阳药科大学 基于肠道octn2载体蛋白设计的前药及其制备方法
CN114470216A (zh) * 2020-10-23 2022-05-13 和记黄埔医药（上海）有限公司 多受体酪氨酸激酶抑制剂与化疗剂的药物组合及其使用方法
CN114522158B (zh) * 2022-01-21 2023-06-27 武汉大学 用于制备治疗肝癌药物的代谢物及其应用
CN115192564B (zh) * 2022-05-23 2023-11-17 四川大学华西医院 一种苯丙氨酸衍生物、药物组合物及其在肿瘤治疗中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
PT1100589E (pt) * 1998-07-30 2005-05-31 Sigma Tau Ind Farmaceuti Utilizacao de propionil-l-carnitina e acetil-l-carnitina na preparacao de medicamentos com actividade anticancerigena
US20030199535A1 (en) * 1998-07-30 2003-10-23 Claudio Cavazza Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
IT1302289B1 (it) * 1998-09-30 2000-09-05 Univ Catania Composizioni farmaceutiche ad attivita' antineoplastica

Also Published As

Publication number Publication date
HK1161114A1 (en) 2012-08-24
JP2012510498A (ja) 2012-05-10
CN102215838A (zh) 2011-10-12
WO2010063696A1 (en) 2010-06-10
EP2361086A1 (en) 2011-08-31
KR20110089402A (ko) 2011-08-08
WO2010063698A1 (en) 2010-06-10
AU2009324183A1 (en) 2010-06-10
CN102215838B (zh) 2014-06-18
US20120208883A1 (en) 2012-08-16
EP2352496A1 (en) 2011-08-10
MX2011005593A (es) 2011-06-20
JP2015098481A (ja) 2015-05-28
US20120093809A1 (en) 2012-04-19
CA2740347A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
EA201170732A1 (ru) Применение алканоил l-карнитина в комбинации с химиотерапевтическими средствами для лечения новообразований
Liu et al. Naphthol-based fluorescent sensors for aluminium ion and application to bioimaging
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
CY1118199T1 (el) Ενωσεις υποκατεστημενης πυραζολο[1,5] πυριμιδινης ως ενδιαμεσα στη συνθεση αναστολεων κινασης trk
EP2551270A3 (en) Pyrazolopyrmidine derivatives for use as pi3 kinase antagonists
EA201001005A1 (ru) Производные 2-бензилпиридазинона в качестве ингибиторов мет киназы
ES2583010T3 (es) Nuevos inhibidores de la ruta de Stat3 e inhibidores de células madre del cáncer
EA201001124A1 (ru) Производные хинолина и их применение в качестве фунгицидов
EA200901611A1 (ru) Производные 2-оксо-3-бензил-бензоксазол-2-она и родственные соединения в качестве ингибиторов мет киназы для лечения опухолей
WO2009108905A3 (en) Fluorescence polarization herg assay
EA201000558A1 (ru) Производные имидазола
EA200701853A1 (ru) Производные циклопентапиридина и тетрагидрохинолина
CR9365A (es) Compuestos y metodos para la inhibicion de la protein-cinasa raf
EA200701191A1 (ru) Утяжелители с покрытием из диспергатора
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
CR11861A (es) Compuestos organicos
EA201000093A1 (ru) Производные пиридазинона
BRPI0607323B8 (pt) composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo
BRPI0812488A2 (pt) Anticorpos anti-cd44 humanizados e quiméricos que mediam citotoxidade de célula de câncer, usos dos mesmos, ensaios de ligação, métodos, composições e kit de ensaio
ECSP077998A (es) Moduladores de cinasa de aminoquinolina y aminoquinazolina
WO2013055417A3 (en) Thiophene based oligomers as light activated biocides
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины
EA201201081A1 (ru) Производные гетарил[1,8]нафтиридина
EA200900767A1 (ru) Антагонистические антитела против ephb3
EA200702071A1 (ru) Новые соединения